AZN: FY25 Deep Dive
FY25 revenue $58.74B (+8.6%) — Oncology $25.6B (+14% ex-2024 milestone), 16 blockbuster medicines, 17 of those growing double-digits. Net income $10.26B (+46%); Diluted EPS $13.08. 100+ Phase 3 trials ongoing; 20 readouts expected in 2026 with potential for >$10B peak revenue. US tariff exemption + manufacturing expansion. Core operating margin 33.3%.
Key Takeaways
AstraZeneca closed fiscal 2025 (calendar year ended December 31, 2025) at $58.74 billion of total revenue, up 8.6% YoY (product revenue +10%) — driven by oncology + biopharma growth. The structural read in the income statement: oncology total revenue grew +14% YoY ex-2024 Lynparza sales milestone to $25.6B; 16 medicines reached blockbuster status (>$1B annual revenue) in 2025, with 17 of those growing at double-digit rates. Net income reached $10.26 billion (+46% from $7.04B FY24); core EPS grew +11%; diluted EPS $13.08 (vs $4.50 FY24, distorted by FY24 Daiichi-Sankyo collaboration accounting). Operating income $13.74B; operating margin ~23% reported / 33.3% core. Free cash flow $11.77B (+62%). Capital allocation: $5.08B in dividends + $720M in buybacks (vs $0 FY24). Total debt $29.7B (slight decline). Pipeline strength: 100+ Phase 3 trials ongoing; 20 Phase 3 readouts expected in 2026 with potential for >$10 billion peak revenue. Strategic moves in 2025: Landmark agreement with US government providing pricing clarity + 3-year tariff exemption; expanding US manufacturing; AZN-Daiichi Datroway commercial launch (US + Europe). 5 prioritized technologies: ADCs, cell therapy, bispecifics + others. Sell-side coverage in window: limited captures — broader analyst universe likely larger but recent activity in Feb-April 2026 not heavily captured.
Main business structure
AstraZeneca reports four therapeutic-area segments:
| Therapeutic Area | FY25 Revenue ($B) | YoY |
|---|---|---|
| Oncology | 25.6 | +14% ex-2024 milestone |
| BioPharmaceuticals (R&I + CVRM) | 23.0 | +5% |
| Rare Disease | 9.1 | +4% |
| Other / Vaccines | ~1.0 | — |
| Total Revenue | 58.74 | +9% |
Oncology (~44% of revenue)
The single largest TA. Q3 + Q4 FY25 highlights:
- Tagrisso (1L EGFR+ NSCLC): Q3 sales $1.9B (+10% Y/Y) — anchor
- Imfinzi + Imjudo: +31% / +14% Q3 growth
- Calquence (BTK CLL): +11% Q3 to $916M
- Lynparza (PARP): +5% Q3 to $837M (alliance with MRK)
- Truqap (AKT inhibitor): +54% Q3 to $193M
- Enhertu (HER2-low ADC, Daiichi alliance): +39% Q3
- Datroway (TROP2 ADC, Daiichi alliance): early uptake US/EU — major FY26 catalyst
US revenue +19% in 9M; emerging markets +20% (excl China); EU strong.
BioPharmaceuticals (~39%)
R&I (Respiratory + Immunology):
- Q4 +10% YoY; growth medicines +27%
- Fasenra +20%; Tezspire (alliance with AMGN) +47%; Breztri +20%; Saphnelo +44%
- Growth medicines >60% of segment revenue
CVRM (Cardiovascular + Renal + Metabolic):
- Q4 -6% YoY on Farxiga (-) + Brilinta (-56%) generic competition
- Lokelma +30%; CVRM flat-to-down outlook
Rare Disease (~16%, post-Alexion acquisition)
- FY25 $9.1B (+4%) — driven by neurology indications + global expansion
- Ultomiris +15-17% (continuing migration from Soliris)
- Strensiq +15-28%
- Koselugo +79% (NF1 plexiform neurofibromas)
- Soliris declining on Ultomiris conversion + biosimilar pressure
Pipeline + Strategic
- 100+ Phase 3 trials ongoing
- 20 readouts expected 2026 with >$10B peak revenue potential
- 5 prioritized technologies: ADCs (Datroway, Enhertu), cell therapy, bispecifics
- 31 regulatory approvals + 16 positive Phase 3 readouts in 2025
- 6 datasets at major conferences (DESTINY-Breast05/11, TROPION-Breast02, Bax24, TULIP-Subcu)
US Operating Environment
- Landmark agreement with US government FY25: pricing clarity + 3-year tariff exemption — major regulatory de-risk
- US manufacturing expansion underway (~$30B aggregate planned)
- Datroway commercial launch US + EU FY25-FY26
Geographic mix. US ~40%, EU ~25%, Emerging Markets ~25%, Other ~10%.
Customer concentration. Specialty distributors per industry standard.
Scale anchors. ~89,000 employees globally. R&D ~$15B annually (~25% of revenue).
Key core metrics (3-year trend)
1. Revenue + the 16-blockbuster franchise
| FY23 | FY24 | FY25 | |
|---|---|---|---|
| Revenue ($B) | 45.81 | 54.07 | 58.74 |
| YoY | — | +18% | +9% |
| Blockbuster medicines | — | — | 16 |
2. Earnings
| FY23 | FY24 | FY25 | |
|---|---|---|---|
| Operating income ($B) | 8.19 | 10.00 | 13.74 |
| Net income ($B) | 5.96 | 7.04 | 10.26 |
| Diluted EPS | $7.62 | $4.50 | $13.08 |
| Core operating margin | ~32% | ~32% | 33.3% (+core) |
The +46% net income on +9% revenue print reflects mix shift toward higher-margin specialty + oncology products.
3. FCF + capital allocation
| FY23 | FY24 | FY25 | |
|---|---|---|---|
| OCF ($B) | 10.35 | 11.86 | 14.58 |
| Capex ($B) | 3.78 | 4.59 | 2.81 |
| FCF ($B) | 6.57 | 7.28 | 11.77 |
| Dividends ($B) | 4.48 | 4.63 | 5.08 |
| Buybacks ($B) | 0 | 0 | 0.72 |
FCF +62% YoY to $11.8B — massive step-up. Capex moderated from $4.6B to $2.8B as buildout phase passed peak. Buyback program launched.
Market evaluation
Sell-side coverage (Feb-April 2026 covered events). Limited captures in window. Broader sell-side universe is large; recent visible activity sparse.
Buy-side positioning. AZN is a core European pharma holding. Trades at premium to legacy pharma on oncology + ADC + Datroway platform. Short interest below 1% of float.
FY25 corporate structure: 16-blockbuster franchise + ADC platform + US tariff de-risk
FY25 was the year AstraZeneca's "16-blockbuster franchise + ADC platform leadership" thesis printed unambiguously. Revenue +9% to $58.7B with oncology +14% to $25.6B; 16 medicines reached blockbuster status; core operating margin held at 33%; FCF +62% to $11.8B. The ADC platform (Enhertu + Datroway, both via Daiichi-Sankyo alliance) is the structural differentiator versus peers. The US government landmark agreement (pricing clarity + 3-year tariff exemption + US manufacturing expansion) removed major near-term regulatory uncertainty. The two FY26 watch items: (1) 20 Phase 3 readouts expected in CY26 — execution on the >$10B peak revenue potential is the central catalyst stack; (2) Datroway commercial launch trajectory (US + EU) — early Datroway uptake will frame the ADC-platform monetization narrative. The Q1 FY26 earnings print this week is the proximate event for measuring continued blockbuster compounding + Datroway initial commercial metrics + pipeline calendar updates.